Drug intelligence / Profile preview

xianlingcao

Development stage: Unknown
Lead developer: Tianjin Tianjiao Pharmaceutical
Administration: Oral

Overview

Xianlingcao is a Traditional Chinese Medicine (TCM) granule formulation developed by Tianjin Tianjiao Pharmaceutical for the treatment of primary non-small cell lung cancer (NSCLC). It is specifically designed for patients diagnosed with the "Qi stagnation and blood stasis" syndrome according to TCM principles. The drug is typically administered orally as an adjuvant therapy in combination with standard chemotherapy. Clinical investigations, such as trial CTR20170065, focus on exploring its effective indications and safety profile in this patient population.

Brand names: Xianlingcao
Other names: Xianlingcao Granules仙苓草颗粒

Beyond the preview

Go deeper on xianlingcao.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xianlingcao.

Explore the full profile